Novartis Seeks Approval for Gleevec in Four Rare Cancers
Novartis Seeks Approval for Gleevec in Four Rare Cancers
EAST HANOVER, New JerseyNovartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.
Articles in this issue
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedule
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
RFA Effective for Single, Small Hepatocellular Carcinoma
New Imaging, ChemoRT Recommendations From NCCN
Panitumumab Improves PFS in Advanced Colon Ca
Studies Question Watchful Waiting for Some Prostate Ca Pts
Growing Evidence Supports Stem Cell Hypothesis of Cancer
FDA Approves New Every-3-Week Dosing for Aranesp
Telephone Often Delivers News of Breast Cancer Diagnosis
IND Submitted for CYT-500
Lower-Dose Thalidomide Effective in Relapsed or Refractory Multiple Myeloma, With Less Toxicity
Zometa Increases BMD in Breast Ca Patients on Femara
Prostate Cancer Recurrence Linked to Surgeon's Skill
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
Automated Voice System Manages Chemo Symptoms
Recent Videos
Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
Bill Seeks to Require Reporting of Extravasated Tissue in Radiology
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Overview and Presentation
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Outlining Ongoing Clinical Developments in Treatment for Rare Lymphomas
Addressing Racial Disparities, Social Barriers to Breast Cancer Care
Related Content
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025Podcast
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
